Visual Defect Diagnosis and Treatment

Diagnostic Testing

A complete diagnostic workup for patients with suspected pituitary macroadenoma is recommended, including dedicated pituitary MRI, comprehensive hormonal evaluation, and visual assessment, followed by appropriate treatment based on tumor characteristics and hormonal status, as recommended by the Endocrine Society 1, 2, 3
Initial imaging should include pre-contrast and post-contrast-enhanced thin-sliced pituitary MRI, using a standard protocol, and consider 3-Tesla MRI for enhanced anatomical definition and improved surgical planning 1
A complete visual evaluation should include visual acuity testing, visual field testing (ideally Goldmann perimetry), fundoscopic examination, and optional color vision evaluation, and consider optical coherence tomography (OCT) as a baseline test for patients with potentially severe visual acuity or visual field defects 1, 4
Physiological pubertal pituitary hypertrophy can mimic adenoma growth in younger patients, highlighting the need for careful evaluation and consideration of alternative diagnoses 2

Transsphenoidal surgery should be offered if visual pathway compression, symptomatic hypopituitarism, documented tumor growth on MRI, or headache attributable to the tumor is present, as recommended by the Endocrine Society 2
Urgent surgical intervention is required if progressive visual deterioration, acute visual threat, or signs of pituitary apoplexy are present, according to the Endocrine Society 2
Indications for surgery include progressive visual deterioration, compression of the optic chiasm, documented tumor growth on MRI, and symptomatic hypopituitarism, as recommended by the American College of Endocrinology and the Endocrine Society 2
Hormone replacement therapy should be initiated for documented deficiencies, including cortisol replacement, thyroid hormone replacement, sex hormone replacement, and growth hormone replacement, as recommended by the Endocrine Society 2, 5
Non-functioning adenomas should not be treated with medical therapy, as recommended by the Endocrine Society 2

Follow-up MRI at 6 months, then at 1, 2, 3, and 5 years, and monitoring for development or worsening of hypopituitarism is essential, although the exact follow-up schedule may vary depending on individual patient needs and guidelines from societies such as the Endocrine Society 2
Post-operative MRI surveillance should be performed at 3 months, 6 months, 1, 2, 3, and 5 years after surgery, with monitoring for hypopituitarism development or worsening, according to the Endocrine Society 2
Consider radiotherapy for residual or recurrent tumor, as recommended by the Endocrine Society 2
For incidental macroadenomas, MRI follow-up should be performed at 6 months, annually for 3 years with gradual reduction thereafter, and lifelong clinical surveillance is recommended, as advised by the Endocrine Society 2
Microincidentalomas (< 10mm) require initial MRI at 12 months, then MRI every 1-2 years for 3 years, with gradual reduction in frequency thereafter, and surveillance can cease after 1-3 years if stable, as suggested by the Endocrine Society 2
Macroincidentalomas (≥ 10mm) require initial MRI at 6 months, then annual MRI for 3 years, with gradual reduction in frequency thereafter, and lifelong clinical surveillance is recommended, as advised by the Endocrine Society 2

Compression of the optic chiasm and development of hypopituitarism are potential complications of pituitary adenomas, as noted by 1
Deterioration of vision is an urgent indication for surgery if vision is threatened, as recommended by the Endocrine Society 2
Central diabetes insipidus at diagnosis is extremely rare in pituitary adenomas and suggests alternative diagnoses, according to the Endocrine Society 2
Rule out other diagnoses that may mimic pituitary macroadenoma, including craniopharyngioma, Rathke's cleft cyst, and germ cell tumors, as recommended by the Endocrine Society 2